Overview

* Viking Therapeutics ( VKTX ) reports Q3 net loss of $90.8 mln, missing analyst expectations

* Company maintains strong cash position of $715 mln to support ongoing clinical trials

* VK2735 Phase 2 VENTURE study shows up to 12.2% weight loss, meeting primary endpoints

Outlook

* Company expects to complete VANQUISH-1 enrollment by end of 2025

* Viking plans to meet with regulators in Q4 to discuss oral VK2735

* Company plans to file IND for amylin agonist program in 1Q26

Result Drivers

* VENTURE STUDY RESULTS - Phase 2 VENTURE study of VK2735 achieved primary and secondary endpoints with up to 12.2% weight loss

* VANQUISH TRIALS PROGRESS - Phase 3 VANQUISH trials for VK2735 in obesity are proceeding on schedule with strong enrollment

* CASH POSITION - Strong cash position of $715 mln supports ongoing clinical trials and development programs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS Miss -$0.81 -$0.67

(16

Analysts

)

Q3 Net Miss -$90.78 -$80.87

Income mln mln (14

Analysts

)

Q3 Miss -$98.56 -$86.14

Income mln mln (14

from Analysts

Operatio )

ns

Q3 $98.56

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Viking Therapeutics Inc ( VKTX ) is $100.00, about 67% above its October 21 closing price of $32.98

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)